Trial Profile
A Survey of Clinical Practice of Adjuvant Treatment of Breast Cancer Using Exemestane (Aromasin?) in Postmenopausal Hr+ Patients.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 17 Apr 2012
Price :
$35
*
At a glance
- Drugs Exemestane (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Acronyms ETAPE
- Sponsors Pfizer
- 30 Nov 2011 Planned end date changed from 1 Feb 2011 to 1 May 2011 as reported by ClinicalTrials.gov.
- 30 Nov 2011 Actual patients number changed from 392 to 398 as reported by ClinicalTrials.gov.
- 24 Mar 2011 Planned end date changed from 1 Feb 2011 to 1 Dec 2010 as reported by ClinicalTrials.gov.